Both our pharmaceutical personnel and quality management system are inherited from well-known international pharmaceutical company (GSK, GlaxoSmithKline), we have extensive experience in PIC/S GMP. Notably, we have produced Japanese encephalitis and tetanus vaccines for the Taiwan Centers for Disease Control (CDC), and we continue to serve as a trusted manufacturing partner for controlled drugs under the commission of TFDA of the Taiwan government. Furthermore, our international recognition is further affirmed by multinational official inspection such as US FDA, Japan PMDA, and Ukraine SMDC. As a testament to our global reach, our products have been exported to the United States, Japan, and other advanced countries, showcasing the exceptional manufacturing capacity, equipment scale, and personnel quality at UBI Pharma Inc.
Grounded in a robust foundation, we remain steadfast in our commitment to adhere to international PIC/S GMP guidelines for pharmaceuticals. Our current capacity for injectable vial is 11.2 million vials annually. And as part of our dedication to meeting the global demand, we expanded the production line from 2022, with an anticipated four-fold increase in production capacity upon startup.
Based in Taiwan, UBI Pharma Inc. holds firm to its belief in providing high-quality business, technology, and manufacturing services to global customers. With a focus on Europe, America, Japan, and beyond, we strive to disseminate our services and products worldwide, making significant contributions to the dynamic field of biotechnology and pharmaceuticals.